ME00819B - 3-supstituisan-[1,2,3]-benzotriazinon jedinjenje za pojačavanje glutamatergičnih sinaptičkih odgovora - Google Patents

3-supstituisan-[1,2,3]-benzotriazinon jedinjenje za pojačavanje glutamatergičnih sinaptičkih odgovora

Info

Publication number
ME00819B
ME00819B MEP-2009-238A MEP23809A ME00819B ME 00819 B ME00819 B ME 00819B ME P23809 A MEP23809 A ME P23809A ME 00819 B ME00819 B ME 00819B
Authority
ME
Montenegro
Prior art keywords
compound
substituted
synaptic responses
treatment
glutamatergic synaptic
Prior art date
Application number
MEP-2009-238A
Other languages
English (en)
French (fr)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of ME00819B publication Critical patent/ME00819B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Ovaj pronalazak se odnosi na prevenciju i lečenje cerebralne insuficijencije, uključujući povećanje funkcionisanja receptora na sinapsarna u moždanim mrežama, koje su odgovorne za ponašanja višeg reda. Ove moždane mreže su uključene u kognitivne sposobnosti, povezane sa memorijskim oštećenjem, kao što se zapažaju kod raznih vrsta demencija i kod neravnoteža u neuronskoj aktivnosti između različitih regiona mozga, kao što se to pretpostavlja u poremećajima, kao što je Parkinsonova bolest, šizofrenija i afektivni poremećaji. U određenom aspektu, ovaj pronalazak se odnosi na jedinjenje, koje je korisno za lečenje takvih stanja i na postupke za korišćenje ovog jedinjenja za takvo lečenje.
MEP-2009-238A 2007-01-03 2007-12-28 3-supstituisan-[1,2,3]-benzotriazinon jedinjenje za pojačavanje glutamatergičnih sinaptičkih odgovora ME00819B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
ME00819B true ME00819B (me) 2012-03-20

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-238A ME00819B (me) 2007-01-03 2007-12-28 3-supstituisan-[1,2,3]-benzotriazinon jedinjenje za pojačavanje glutamatergičnih sinaptičkih odgovora

Country Status (38)

Country Link
US (1) US8173644B2 (me)
EP (1) EP2144506B1 (me)
JP (1) JP5139446B2 (me)
CN (1) CN101616592B (me)
AP (1) AP2502A (me)
AR (1) AR064740A1 (me)
AT (1) ATE527269T1 (me)
AU (1) AU2007342365B2 (me)
BR (1) BRPI0720749A2 (me)
CA (1) CA2674460C (me)
CR (1) CR10906A (me)
CU (1) CU23804B7 (me)
CY (1) CY1112493T1 (me)
DK (1) DK2144506T3 (me)
EA (1) EA017437B1 (me)
EC (1) ECSP099499A (me)
ES (1) ES2374995T3 (me)
GE (1) GEP20125438B (me)
GT (1) GT200900189A (me)
HK (1) HK1140105A1 (me)
HN (1) HN2009001268A (me)
HR (1) HRP20110970T1 (me)
IL (1) IL199651A (me)
MA (1) MA31160B1 (me)
ME (1) ME00819B (me)
MX (1) MX2009007242A (me)
MY (1) MY154877A (me)
NI (1) NI200900131A (me)
NZ (1) NZ578293A (me)
PL (1) PL2144506T3 (me)
PT (1) PT2144506E (me)
RS (1) RS52108B (me)
SG (1) SG163545A1 (me)
SI (1) SI2144506T1 (me)
SV (1) SV2009003322A (me)
TN (1) TN2009000277A1 (me)
WO (1) WO2008085506A1 (me)
ZA (1) ZA200904826B (me)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007342364A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
SG163526A1 (en) 2007-08-10 2010-08-30 Cortex Pharma Inc Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
EP2784065B1 (en) 2011-11-22 2016-10-05 Beijing Medisan Technology Co. Ltd. Glycine reuptake inhibitor and use thereof
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) * 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
AU2016284654B9 (en) 2015-06-26 2020-05-21 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
ATE215079T1 (de) 1992-07-24 2002-04-15 Univ California Arzneimittel, die den durch ampa rezeptoren vermittelten synaptischen respons erhöhen
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
DE59504622D1 (de) * 1994-10-31 1999-02-04 Merck Patent Gmbh Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US6030968A (en) 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
HUP0101280A3 (en) 1998-02-18 2003-02-28 Neurosearch As Positive ampa receptor modulator compounds and their use
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
EA011034B1 (ru) * 2001-11-26 2008-12-30 Кортекс Фармасеутикалс, Инк. Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
KR20050094840A (ko) * 2003-01-13 2005-09-28 코텍스 파마슈티칼스, 인크. 수면 부족 및 스트레스로 인한 인식 저하의 치료방법
GB0317482D0 (en) 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2007342364A1 (en) 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
US8013003B2 (en) 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
SG163526A1 (en) 2007-08-10 2010-08-30 Cortex Pharma Inc Bicyclic amides for enhancing glutamatergic synaptic responses
WO2009038752A2 (en) * 2007-09-20 2009-03-26 Cortex Pharmaceuticals, Inc. 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses

Also Published As

Publication number Publication date
HRP20110970T1 (hr) 2012-01-31
NZ578293A (en) 2012-01-12
NI200900131A (es) 2010-03-11
MY154877A (en) 2015-08-14
AU2007342365B2 (en) 2012-11-15
CU23804B7 (es) 2012-03-15
MA31160B1 (fr) 2010-02-01
MX2009007242A (es) 2009-09-02
GT200900189A (es) 2011-08-02
ES2374995T3 (es) 2012-02-23
IL199651A (en) 2015-08-31
EP2144506A1 (en) 2010-01-20
EP2144506A4 (en) 2010-05-05
TN2009000277A1 (en) 2010-10-18
PL2144506T3 (pl) 2012-04-30
IL199651A0 (en) 2010-04-15
RS52108B (en) 2012-08-31
US20100137295A1 (en) 2010-06-03
JP2010514838A (ja) 2010-05-06
CA2674460C (en) 2014-07-15
HN2009001268A (es) 2011-12-27
CR10906A (es) 2009-10-23
ZA200904826B (en) 2010-09-29
HK1140105A1 (en) 2010-10-08
US8173644B2 (en) 2012-05-08
DK2144506T3 (da) 2012-03-05
AP2502A (en) 2012-10-23
CN101616592A (zh) 2009-12-30
CN101616592B (zh) 2013-06-05
CA2674460A1 (en) 2008-07-17
BRPI0720749A2 (pt) 2014-01-14
ECSP099499A (es) 2009-10-30
EA017437B1 (ru) 2012-12-28
GEP20125438B (en) 2012-03-26
SV2009003322A (es) 2010-02-05
AU2007342365A1 (en) 2008-07-17
ATE527269T1 (de) 2011-10-15
AR064740A1 (es) 2009-04-22
SI2144506T1 (sl) 2012-01-31
WO2008085506A1 (en) 2008-07-17
EP2144506B1 (en) 2011-10-05
CY1112493T1 (el) 2015-12-09
CU20090117A7 (es) 2011-10-05
AP2009004931A0 (en) 2009-08-31
SG163545A1 (en) 2010-08-30
EA200900925A1 (ru) 2009-12-30
PT2144506E (pt) 2011-12-21
JP5139446B2 (ja) 2013-02-06

Similar Documents

Publication Publication Date Title
ME00819B (me) 3-supstituisan-[1,2,3]-benzotriazinon jedinjenje za pojačavanje glutamatergičnih sinaptičkih odgovora
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
DE602006008456D1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
BRPI0817271A2 (pt) Método de tratamento da doença de parkinson e outros distúrbios relacionados
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
UY28817A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegerativos
EA201100461A1 (ru) Спиро-трициклические соединения как модуляторы бета-секретазы и способы их использования
BR112013022039A2 (pt) derivados 6,7-di-hidro-pirazol[1,5-a]pirazin-4-ilamina úteis como inibidores de beta-secretase (bace)
BRPI0515528A (pt) n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central
EA201491534A1 (ru) Ингибиторы бета-секретазы
CO6731117A2 (es) Metodos para diagnosticar y tratar desórdenes relacionados con la longitud axial del ojo
EA201491116A1 (ru) Производные 6-дифторметил-5,6-дигидро-2h-[1,4]оксазин-3-амина
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
BRPI0817433A2 (pt) Moduladores de gama-secretase piperidinila e piperazinila
IN2014DN09826A (me)
BR0214425A (pt) Compostos carbonilbenzoxazina para aperfeiçoamento de respostas sinápticas glutamatérgicas
MX356814B (es) Métodos y composiciones para neuroprotección.
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
MA47595A (fr) Méthodes de traitement d'affections neurodégénératives
WO2011123842A9 (en) Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain
BR112018012343A2 (pt) composições de benzofenonas poli-hidroxiladas e métodos de tratamento de distúrbios neurodegenerativos
EA201992108A1 (ru) Ингибиторы бета-секретазы